Tailwinds’ Take: Lysosomal Storage Disorders is an area in which Transcend should be highly effective. Dr. Scarpa is also presenting at this course, after which I wouldn’t be surprised to see something announced in conjunction with him regarding a LSD trial. It appears that Dr. Mark Day has completed his internal work since joining biOasis and now will be getting more involved as the external face of the company, which should be a significantly positive development.
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, chief executive officer, will present at the 16th International Postgraduate Course on Lysosomal Storage Disorders, in Nierstein (Mainz), Germany on June 07 – 10, 2017.
Dr. Day’s presentation, “Improving the Probability of Success in CNS Drug Discovery and Development: A Case Study,” targets issues relating to therapies to treat the central nervous system (CNS). The workshop is academic in nature and will be attended by scientists from companies and institutions that are focused on lysosomal storage diseases.
Lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders, some of which cause significant impairments in neurological function. The disorders are caused by dysfunctional or missing enzymes that are required for the processing and removal of unwanted cellular materials.
Several LSDs can be treated with enzyme replacement therapy, the intravenous infusion of a solution containing the missing enzyme. However, the blood-brain barrier blocks most therapeutics, including enzymes, from entering the CNS in sufficient quantities to effectively treat neurological disorders. The inability of most therapeutics to enter the CNS has resulted in areas of great unmet medical need.
“Our Transcend peptide technology specifically addresses the issue of delivery of therapeutics across the blood-brain barrier,” said Dr. Mark Day, CEO of biOasis. “From the preclinical data we’ve generated to date, we are excited to move several targets, including enzymes, antibodies and small molecules, through de-risking imaging studies and into clinical assessment. This workshop allows me to meet with many of the stakeholders in this very key market for us.”
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the brain-blood barrier. The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company, please visit www.bioasis.ca.
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
On Behalf of the Board of Directors
Dr. Mark Day, CEO
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”
biOasis Technologies Inc.
1- (403) 561-8989